All In Biotech

Free tool

FAERS Monitor: Naftin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019599 or its brand name (Naftin, Naftifine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

334

Serious

161

48% of reports

Hospitalization

68

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus33
  • blister27
  • skin exfoliation26
  • hypersensitivity25
  • chronic kidney disease24
  • drug ineffective24
  • rash23
  • erythema21
  • off label use20
  • diarrhoea18
  • pain18
  • renal failure18
  • acute kidney injury15
  • burning sensation13
  • headache12

Reports by year received

View as table
YearReports
20061
20072
20082
20092
20103
20119
201214
201312
201414
201534
201646
201724
201832
201933
202028
202123
202218
202313
20249
202510
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blisterSignal2730.321.1737
chronic kidney diseaseSignal2419.913.5413
skin exfoliationSignal2619.413.4437
burning sensationSignal1311.76.9117
renal failureSignal188.55.4113
hypersensitivitySignal258.55.8159
erythemaSignal216.44.392
acute kidney injurySignal156.23.860
pruritusSignal335.43.9116
rashSignal233.32.236
pain181.81.26
diarrhoea181.81.15
off label use201.40.92
headache121.20.70
drug ineffective241.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.